CDSS Scientist joins Murdoch University's IIID

Published on

A man standing in a corridor

Best Wishes Andy!

We wish Dr Andrew Gibson well as he moves to a new position at Murdoch University in Perth Australia. He is joining the Institute of Immunology and Infectious Diseases (IIID) as a Research Fellow of Drug Hypersensitivity.

Andrew joined the MRC Centre for Drug Safety Science eight years ago, completing his Masters and PhD with us, then beginning his post-doc studies. His research explored the susceptibility factors that impact on development of drug hypersensitivity.

For 15 years we have known that drug antigen exposure and the availability of HLA and T-cell receptors are important. However, most individuals expressing these factors to not develop hypersensitivity. Andrew's research identified immune checkpoints (PD-1, CTLA-4) as key determinants of whether genetically predisposed individuals develop hypersensitivity after drug exposure.

The Drug Hypersensitivity research group at IIID, led by Prof Elizabeth Phillips is focused on investigating the immunological mechanisms driving allergic reactions to drugs.

We wish Andrew all the very best for the future!

Click here for more information on the Institute of Immunology and Infectious Diseases (IIID).

Click here for more information on the MRC Centre for Drug Safety Science (CDSS).